🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

122 results for “Beone Medicines Ireland Limited” Clear

  1. BGB-11417, BGB-11417 placebo, BGB-11417, BGB-11417, BGB-11417, Zanubrutinib

    Beone Medicines Ireland Limited

    relapsed or refractory mantle cell lymphoma (R/R MCL)

    phase 3 small molecule active

    1 trial

  2. BGB-11417, Zanubrutinib, BGB-11417, Venclyxto 100 mg film-coated tablets, Gazyvaro 1,000 mg concentrate for solution for infusion., BGB-11417, BGB-11417

    Beone Medicines Ireland Limited

    Previously Untreated Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  3. BGB-16673

    Beone Medicines Ireland Limited

    CLL

    phase 3 small molecule active

    1 trial

  4. BGB-16673

    Beone Medicines Ireland Limited

    Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    2 trials

  5. BGB-43395

    Beone Medicines Ireland Limited

    HR+/HER2- Breast Cancer

    phase 3 small molecule active

    1 trial

  6. Jaypirca 100 mg film-coated tablets, BGB-16673, BGB-16673

    Beone Medicines Ireland Limited

    Chronic lymphocytic leukemia (CLL), Small lymphocytic lymphoma (SLL)

    phase 3 small molecule active

    1 trial

  7. Ociperlimab, Ociperlimab, Pamiparib, Pamiparib, Tislelizumab

    Beone Medicines Ireland Limited

    Solid tumors and hamatological malignancies

    phase 3 small molecule active

    1 trial

  8. Pamiparib capsule

    Beone Medicines Ireland Limited

    Ovarian Cancer

    phase 3 small molecule active

    1 trial

  9. Sonrotoclax

    Beone Medicines Ireland Limited

    Mantle Cell Lymphoma

    phase 3 small molecule active

    1 trial

  10. Sonrotoclax

    Beone Medicines Ireland Limited

    CLL

    phase 3 small molecule active

    1 trial

  11. Sonrotoclax

    Beone Medicines Ireland Limited

    Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    4 trials

  12. Subcutaneous Tislelizumab

    Beone Medicines Ireland Limited

    Metastatic Gastric Adenocarcinoma

    phase 3 small molecule active

    1 trial

  13. Tislelizumab

    Beone Medicines Ireland Limited

    Urothelial Carcinoma

    phase 3 small molecule active

    1 trial

  14. Tislelizumab

    Beone Medicines Ireland Limited

    Non Small Cell Lung Cancer

    phase 3 small molecule active

    4 trials

  15. Tislelizumab

    Beone Medicines Ireland Limited

    Classical Hodgkin Lymphoma

    phase 3 small molecule terminated

    1 trial

  16. Tislelizumab

    Beone Medicines Ireland Limited

    Esophageal Squamous Cell Carcinoma (ESCC)

    phase 3 small molecule completed

    1 trial

  17. Tislelizumab

    Beone Medicines Ireland Limited

    Advanced Malignancies

    phase 3 small molecule active

    1 trial

  18. Tislelizumab 300 mg solution for injection, Tevimbra 100 mg concentrate for solution for infusion

    Beone Medicines Ireland Limited

    Locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma

    phase 3 small molecule active

    1 trial

  19. Venclyxto 10 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, BGB-11417, MabThera 100 mg concentrate for solution for infusion, BGB-11417, BGB-11417, Gazyvaro 1,000 mg concentrate for solution for infusion., BGB-11417, MabThera 500 mg concentrate for solution for infusion, Venclyxto 50 mg film-coated tablets

    Beone Medicines Ireland Limited

    Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  20. Venclyxto 100 mg film-coated tablets, Levact 2,5 mg/ml poudre pour solution à diluer pour perfusion, BGB-16673, BGB-16673, Venclyxto 10 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, MabThera 500 mg concentrate for solution for infusion, MabThera 100 mg concentrate for solution for infusion, Zydelig 150 mg film-coated tablets, Zydelig 100 mg film-coated tablets

    Beone Medicines Ireland Limited

    Chronic lymphotic leukemia and Small Lymphocytic lymphoma

    phase 3 small molecule active

    1 trial

  21. Venclyxto 100 mg film-coated tablets, MabThera 500 mg concentrate for solution for infusion, Zanubrutinib, Venclyxto 50 mg film-coated tablets

    Beone Medicines Ireland Limited

    Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  22. Zanidatamab

    Beone Medicines Ireland Limited

    Gastric Neoplasms

    phase 3 small molecule active

    1 trial

  23. Zanubrutinib

    Beone Medicines Ireland Limited

    B-cell malignancies

    phase 3 small molecule active

    1 trial

  24. Zanubrutinib

    Beone Medicines Ireland Limited

    B-cell Malignancies

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources